At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MNMD Mind Medicine (MindMed) Inc.
Market Closed 12-20 16:00:00 EST
7.16
+0.15
+2.07%
盘后7.16
+0.000.00%
19:45 EST
High7.36
Low6.92
Vol1.77M
Open6.96
D1 Closing7.02
Amplitude6.17%
Mkt Cap525.05M
Tradable Cap482.88M
Total Shares73.33M
T/O12.65M
T/O Rate2.62%
Tradable Shares67.44M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Chardan Initiates Coverage on Mind Medicine With Buy Rating, $20 Price Target
MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company also develops MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. The company is headquartered in New York, New York.